The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Myopia
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Randomized control trialMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 5 years and 9 years
- Gender
- Both males and females
Description
High risk children (with family history of myopia) with low hyperopia or low myopia will be randomized to atropine or placebo, with 2 -2.5 year treatment and 1 year washout.
High risk children (with family history of myopia) with low hyperopia or low myopia will be randomized to atropine or placebo, with 2 -2.5 year treatment and 1 year washout.
Tracking Information
- NCT #
- NCT03140358
- Collaborators
- National Medical Research Council (NMRC), Singapore
- Investigators
- Principal Investigator: Audrey Chia Singapore National Eye Center
Get Well Soon